News

• AstraZeneca's Q4 revenue down by 7% to $11.21B
  02/09/2023 / 08:08 - TeleTrader
•  
• FDA halts use of Evusheld due to low effectiveness
  01/27/2023 / 06:40 - TeleTrader
•  
• AstraZeneca signs COVID treatment deal with China
  01/13/2023 / 11:10 - TeleTrader
•  
• AstraZeneca to acquire Neogene for $320M
  11/29/2022 / 10:08 - TeleTrader
•  
• AstraZeneca's Q3 revenue soars 11% to $10.9B
  11/10/2022 / 08:05 - TeleTrader
•  
• AstraZeneca user error exposed patient data - report
  11/03/2022 / 17:52 - TeleTrader
•  
• AstraZeneca's Q2 revenue up 31% to $10.8B
  07/29/2022 / 08:02 - TeleTrader
•  
• AstraZeneca to acquire TeneoTwo for $1.27 billion
  07/05/2022 / 08:40 - TeleTrader
•  
• AstraZeneca, Samsung Biologics shut down joint venture - report
  05/24/2022 / 07:05 - TeleTrader
•  
• AstraZeneca's Q1 core EPS rises 16% to $1.89
  04/29/2022 / 08:06 - TeleTrader
•  
• Canada approves AstraZeneca's Evusheld
  04/14/2022 / 17:37 - TeleTrader
•  
• EMA backs AstraZeneca's COVID drug for prevention
  03/24/2022 / 17:44 - TeleTrader
•  
• AstraZeneca may give up seeking US jab approval
  03/17/2022 / 17:08 - TeleTrader
•  
• HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer
  03/07/2022 / 05:30 - GlobeNewswire
•  
• HUTCHMED Reports 2021 Full Year Results and Provides Business Updates
  03/03/2022 / 13:00 - GlobeNewswire